Get started
Author

Jae Hui Kim

Observed names: J H Kim, Jae H. Kim
ORCID: 0000-0001-8121-6353
Observed ORCID: 0000-0001-8121-6353
OpenAlex ID: A5121898249
Temporal changes in foveal contour after macular hole surgery
2014 · J H Kim, S W Kang, et al. · Eye · 4
PDF
Comparison of Initial Loading Injection Outcomes Between Aflibercept 8 Mg and Faricimab in Neovascular Age-related Macular Degeneration
2026 · Hee Yong Han, Sang Min Park, et al. · Retina · 2
Short-term outcomes and choroidal morphological changes following aflibercept therapy in pachychoroid neovasculopathy
2026 · Jae Hui Kim, Sang Min Park, et al. · Scientific Reports · 2
PDF
Long-term clinical outcomes and prognostic factors of central serous chorioretinopathy
2026 · Dong Gyu Na, Chul Gu Kim, et al. · BMC Ophthalmology · 1
PDF
Design and Baseline Characteristics of the Korean Age-Related Maculopathy Study (KARMS): A Nationwide Multicenter Prospective Observational Study
2026 · Sungsoon Hwang, Se Woong Kang, et al. · Ophthalmology Science · 1
PDF
Clinical Factors, Treatment Selection, and Outcomes in Postcataract Fungal Endophthalmitis from Contaminated Viscoelastics
2023 · Jae Hui Kim, Mihyun Choi, et al. · Ophthalmology Retina · 1
Progression to Advanced Age-Related Macular Degeneration in Drusen-Driven and Pachychoroid-Driven Disease: The Korean Age-Related Maculopathy Study
2026 · Sungsoon Hwang, Se Woong Kang, et al. · Ophthalmology Science
PDF
Short-Term Outcomes of Switching from the Aflibercept Biosimilar SB15 to Ranibizumab Biosimilars
2026 · Dong Gyu Na, Sang Min Park, et al. · Journal of the Korean Ophthalmological Society
PDF
PROGNOSTIC FACTORS FOR CLINICAL OUTCOMES AND LESION REACTIVATION IN STAGE 2 to 3 TYPE 3 MACULAR NEOVASCULARIZATION TREATED USING a TREAT-AND-EXTEND REGIMEN
2026 · Yeji Kim, Sang M. Park, et al. · Retina
Persistent subretinal fluid in neovascular AMD: clinical significance and implications for treatment
2026 · Jae Hui Kim · Expert Opinion on Biological Therapy
Comparison of Treatment Outcomes Between the Ranibizumab Biosimilar CKD-701 and Bevacizumab in Idiopathic Choroidal Neovascularization
2026 · So Hyun Yu, Sang Min Park, et al. · Journal of the Korean Ophthalmological Society
PDF
Short-term treatment outcomes of the ranibizumab biosimilar CKD-701 for vitreous hemorrhage secondary to proliferative diabetic retinopathy
2026 · So Hyun Yu, Jaejin Cho, et al. · BMC Ophthalmology
Twelve-month lesion reactivation after initial loading injections of faricimab in neovascular AMD: a comparison between three and four loading injections
2026 · Hee Yong Han, Sang Min Park, et al. · BMC Ophthalmology
Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion
2026 · Jaejin Cho, Sang Min Park, et al. · BMC Ophthalmology
Risk Factors and Quality of Life in Patients With Geographic Atrophy, a Late Stage of Age-Related Macular Degeneration: Findings From the Korea National Health and Nutrition Examination Survey
2026 · Yeji Kim, Yun Tae Kim, et al. · Journal of Korean Medical Science
PDF
Uncertainty-Aware Selective Prediction of Neovascular Age-Related Macular Degeneration Recurrence Using Artificial Intelligence
2026 · Won Tae Yoon, Hun-Gyeom Kim, et al. · IEEE Access
Injection Frequency and Differences in Visual Outcomes based on Diagnosis Year in Neovascular Age-related Macular Degeneration
2024 · Jae Hui Kim, Kyung Hye Kang, et al. · Journal of the Korean Ophthalmological Society
PDF
Works count: 17
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type